Throughout the past year, Zimmer Biomet Holdings ZBH has faced a mixed performance, interspersed with occasional losses. The company recently issued a warning over the potential impact of a software switch, fueling a subsequent drop in stock prices. However, analysts recognize Zimmer Biomet as a value and momentum stock. Despite a notable investment cut by Texas Permanent School Fund Corp, financial entities like Forsta AP Fonden maintain significant stock holdings in Zimmer Biomet. The company has announced its financial results for second and third quarters of 2024, along with its plans to acquire OrthoGrid Systems. Advancing its offerings, Zimmer Biomet has struck a distribution deal with THINK Surgical. In addition to participation in healthcare conferences and the appointment of new board members, Zimmer Biomet has also received FDA approval for the ROSA® Shoulder System, an innovative entry in shoulder replacement surgery. Nevertheless, the performance of Zimmer Biomet Holdings has been inconsistent, causing losses for long-term investors. Despite these setbacks, ZBH's robust revenue growth and regular dividends restore investor confidence.
Zimmer Biomet Holdings ZBH News Analytics from Tue, 07 Nov 2023 08:00:00 GMT to Sun, 15 Sep 2024 11:03:55 GMT -
